•
Dec 31, 2021

Natera Q4 2021 Earnings Report

Natera reported a 53.9% increase in total revenues driven by product revenues growth.

Key Takeaways

Natera's Q4 2021 total revenues increased by 53.9% compared to Q4 2020, driven by product revenue growth. The company processed 438,800 tests in the fourth quarter of 2021, including 424,200 tests accessioned in its laboratory.

Total revenues were $173.0 million, a 53.9% increase compared to Q4 2020.

Product revenues were $160.9 million, a 51.1% increase compared to Q4 2020.

Approximately 438,800 tests were processed in Q4 2021.

Net loss for the fourth quarter of 2021 was $140.6 million, or ($1.48) per diluted share.

Total Revenue
$173M
Previous year: $112M
+53.9%
EPS
-$1.48
Previous year: -$0.89
+66.3%
Tests Processed
438.8K
Previous year: 295K
+48.7%
Tests Accessioned
424.2K
Previous year: 281K
+51.0%
Total Tests Reported
410.9K
Previous year: 281.4K
+46.0%
Gross Profit
$78.9M
Previous year: $52.5M
+50.3%
Cash and Equivalents
$915M
Previous year: $738M
+24.0%
Free Cash Flow
-$108M
Previous year: -$80.8M
+33.3%
Total Assets
$1.24B
Previous year: $932M
+32.6%

Natera

Natera

Forward Guidance

Natera anticipates 2022 total revenue of $770 million to $790 million; 2022 gross margin to be approximately 46% to 48% of revenues; selling, general and administrative costs to be approximately $560 million to $590 million; research and development costs to be $340 million to $360 million, and net cash consumption to be $370 million to $400 million.